Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Minu K Srivastava

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
Oncoimmunology|December 25, 2012
Targeting MDSCs enhance therapeutic vaccination responses against lung cancerMinu K Srivastava, Steven Dubinett, Sherven Sharma
Expert Opinion on Biological Therapy|June 30, 2011
MUC1 peptide vaccine mediated antitumor activity in non-small cell lung cancerSherven Sharma, Minu K Srivastava, Marni Harris-White, et al.
American Journal of Cancer Research|August 27, 2013
Effect of epigenetic histone modifications on E-cadherin splicing and expression in lung cancerWei Liao, Gwen Jordaan, Minu K Srivastava, et al.
Cancer Research|December 24, 2009
Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteineMinu K Srivastava, Pratima Sinha, Virginia K Clements, et al.
Cancer Immunology, Immunotherapy : CII|January 4, 2021
APX005M, a CD40 agonist antibody with unique epitope specificity and Fc receptor binding profile for optimal therapeutic applicationErin L Filbert, Pia K Björck, Minu K Srivastava, et al.
International Journal of Cancer|May 18, 2010
MHC II lung cancer vaccines prime and boost tumor-specific CD4+ T cells that cross-react with multiple histologic subtypes of nonsmall cell lung cancer cellsMinu K Srivastava, Jacobus J Bosch, Ashley L Wilson, et al.
Nature Methods|October 24, 2007
The reverse in-gel kinase assay to profile physiological kinase substratesXiang Li, Bin Guan, Minu K Srivastava, et al.
Oncoimmunology|July 29, 2016
Tetraspanin CD81, a modulator of immune suppression in cancer and metastasisFelipe Vences-Catalán, Ranjani Rajapaksa, Minu K Srivastava, et al.
JAMA Network Open|May 3, 2024
Response- and Progression-Based End Points in Trial and Observational Cohorts of Patients With NSCLCYichen Lu, Spencer S Langerman, Emily McCain, et al.
Immunotherapy|March 10, 2012
Myeloid suppressor cells and immune modulation in lung cancerMinu K Srivastava, Åsa Andersson, Li Zhu, et al.
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Oncoimmunology|December 25, 2012
Targeting MDSCs enhance therapeutic vaccination responses against lung cancerMinu K Srivastava, Steven Dubinett, Sherven Sharma
Expert Opinion on Biological Therapy|June 30, 2011
MUC1 peptide vaccine mediated antitumor activity in non-small cell lung cancerSherven Sharma, Minu K Srivastava, Marni Harris-White, et al.
American Journal of Cancer Research|August 27, 2013
Effect of epigenetic histone modifications on E-cadherin splicing and expression in lung cancerWei Liao, Gwen Jordaan, Minu K Srivastava, et al.
Cancer Research|December 24, 2009
Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteineMinu K Srivastava, Pratima Sinha, Virginia K Clements, et al.
Cancer Immunology, Immunotherapy : CII|January 4, 2021
APX005M, a CD40 agonist antibody with unique epitope specificity and Fc receptor binding profile for optimal therapeutic applicationErin L Filbert, Pia K Björck, Minu K Srivastava, et al.
International Journal of Cancer|May 18, 2010
MHC II lung cancer vaccines prime and boost tumor-specific CD4+ T cells that cross-react with multiple histologic subtypes of nonsmall cell lung cancer cellsMinu K Srivastava, Jacobus J Bosch, Ashley L Wilson, et al.
Nature Methods|October 24, 2007
The reverse in-gel kinase assay to profile physiological kinase substratesXiang Li, Bin Guan, Minu K Srivastava, et al.
Oncoimmunology|July 29, 2016
Tetraspanin CD81, a modulator of immune suppression in cancer and metastasisFelipe Vences-Catalán, Ranjani Rajapaksa, Minu K Srivastava, et al.
JAMA Network Open|May 3, 2024
Response- and Progression-Based End Points in Trial and Observational Cohorts of Patients With NSCLCYichen Lu, Spencer S Langerman, Emily McCain, et al.
Immunotherapy|March 10, 2012
Myeloid suppressor cells and immune modulation in lung cancerMinu K Srivastava, Åsa Andersson, Li Zhu, et al.
Pageof 4